GlassScriptPhysician profile
Tiffany Lee Tello
NPI 1457793283
$5,431.37
in general payments reported to CMS, 2019-2025
31 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $51.23 · 2021: $400 · 2022: $807 · 2023: $1,073 · 2024: $1,122 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,534.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,350.72 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $566.28 | 2019-2025 | Ilumya, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $491.93 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $417.27 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $313.77 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $290.48 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $274.51 | 2025 | Nemluvio |
| Genzyme Corporation | $245.89 | 2019-2025 | |
| Allergan, INC. | $214.20 | 2020-2022 | |
| Ucb, INC. | $193.65 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $165.73 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $129.44 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $129.04 | 2019-2024 | |
| Mimedx Group, INC. | $110.61 | 2024-2025 | |
| Incyte Corporation | $84.79 | 2023-2025 | Opzelura |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $69.30 | 2019-2022 | |
| Merz North America, INC. | $45.44 | 2020-2021 | |
| Pfizer INC. | $41.06 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $35.82 | 2023-2024 | Zoryve |
| Celgene Corporation | $34.51 | 2019 | |
| Dermavant Sciences, INC. | $33.94 | 2023 | Vtama |
| Journey Medical Corporation | $33.34 | 2023-2025 | |
| Kerecis Limited | $32.64 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Dermira, INC. | $22.27 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.00 | 2024 | Nuzyra |
| Boston Scientific Corporation | $16.82 | 2025 | Angiojet Ultra 5000a |
| Organon LLC | $16.14 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.02 | 2020 | |
| Prugen, INC. Pharmaceuticals | $14.22 | 2019 | |
| Mayne Pharma Commercial LLC | $11.97 | 2019 | |
| Merck Sharp & Dohme LLC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Tello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.